Prasad
Biotech

CBER Director Vinay Prasad to depart FDA—again

Prasad has drawn increased criticism throughout his tenure, especially from the rare disease community.
Darren Incorvaia Mar 6, 2026 5:30pm
multiple myeloma cells blood flow cancer blood cancer

BMS' CELMoD drug improves myeloma PFS in phase 3

Mar 9, 2026 11:08am
How physiology powers biotech innovation

How physiology powers biotech innovation

Brought to you by American Physiological Society
home run

Xenon epilepsy candidate 'blows away' ph. 3 expectations

Mar 9, 2026 10:55am
Woman choking and coughing

FDA greenlights backup anti-choking suction device

Mar 9, 2026 10:45am
Graphic of a puzzle depicting both the US and Chinese flags with missing pieces bridging the two together

Tenacia pens $308M Rapport deal for China rights to epilepsy med

Mar 9, 2026 10:30am
More News

AbbVie ties $350M bet to almost 10% weight loss after 12 weeks

Mar 9, 2026 9:50am

Pfizer ramps up plans for trispecific after ph. 2 eczema win

Mar 9, 2026 9:10am

Regeneron's obesity drug shows Zepbound-like efficacy in phase 3

Mar 9, 2026 8:25am

Alfasigma's $690M deal for GSK itch drug awaiting FDA decision

Mar 9, 2026 6:55am